** U.S.-listed shares of Merus NV MRUS.O down 6.3% to $58.50 post-market as co seeks equity raise
** Dutch biotech firm launches stock offering; targeted raise not disclosed
** Co plans to use net offering proceeds to advance clinical development of its product candidates, for preclinical research and technology development, and for working capital among other purposes
** Jefferies, BofA, Leerink, Guggenheim, Truist and LifeSci Capital are jt bookrunners
** On May 23, MRUS shares surged ~33% to close at $55.14 after co's lead candidate petosemtamab in combination with Merck's MRK.N Keytruda delayed progression of a type of head and neck cancer in a mid-stage trial
** MRUS shares on Tues finished up 6.6% at $62.42, up 50% over the past seven sessions
** Co has ~69.2 mln shares outstanding for $4.3 bln market cap
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.